136 related articles for article (PubMed ID: 1761814)
1. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism.
Mariotti S; Caturegli P; Barbesino G; Del Prete GF; Chiovato L; Pinchera A
J Endocrinol Invest; 1991 Oct; 14(9):777-81. PubMed ID: 1761814
[TBL] [Abstract][Full Text] [Related]
2. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases.
Mariotti S; Caturegli P; Barbesino G; Marinò M; Del Prete GF; Chiovato L; Tonacchera M; De Carli M; Pinchera A
Clin Endocrinol (Oxf); 1992 Nov; 37(5):415-22. PubMed ID: 1486691
[TBL] [Abstract][Full Text] [Related]
3. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.
Koukkou E; Panayiotidis P; Alevizou-Terzaki V; Thalassinos N
J Clin Endocrinol Metab; 1991 Oct; 73(4):771-6. PubMed ID: 1909702
[TBL] [Abstract][Full Text] [Related]
4. Decreased serum level of IL-7 in patients with active Graves' disease.
Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
[TBL] [Abstract][Full Text] [Related]
5. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs.
Tsatsoulis A; Vlachoyiannopoulos PG; Dalekos GN; Johnson EO; Moutsopoulos HM
Eur J Clin Invest; 1995 Sep; 25(9):654-8. PubMed ID: 7498238
[TBL] [Abstract][Full Text] [Related]
6. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
[TBL] [Abstract][Full Text] [Related]
7. Dynamic changes in soluble interleukin-2 receptor levels during treatment of Graves' disease. Correlation with disease activity.
Weryha G; Gobert B; Leclère J; Béné MC; Faure G; Hartemann P
Horm Res; 1991; 35(1):8-12. PubMed ID: 1916654
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
[TBL] [Abstract][Full Text] [Related]
9. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
Salvi M; Girasole G; Pedrazzoni M; Passeri M; Giuliani N; Minelli R; Braverman LE; Roti E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2976-9. PubMed ID: 8768861
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble interleukin-2 receptors as an index of the biological activity of thyroid hormones in hyperthyroidism.
Koukkou E; Panayiotidis P; Thalassinos N
J Endocrinol Invest; 1995 Apr; 18(4):253-7. PubMed ID: 7560805
[TBL] [Abstract][Full Text] [Related]
11. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balazs C; Farid NR
J Autoimmun; 1991 Aug; 4(4):681-8. PubMed ID: 1777014
[TBL] [Abstract][Full Text] [Related]
12. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease.
Escobar-Morreale HF; Serrano-Gotarredona J; Villar LM; García-Robles R; González-Porqué P; Sancho JM; Varela C
Thyroid; 1996 Feb; 6(1):29-36. PubMed ID: 8777381
[TBL] [Abstract][Full Text] [Related]
13. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 1999 Nov; 84(11):4012-6. PubMed ID: 10566642
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of serum interleukin-18 in Graves' disease.
Miyauchi S; Matsuura B; Onji M
Thyroid; 2000 Sep; 10(9):815-9. PubMed ID: 11041460
[TBL] [Abstract][Full Text] [Related]
15. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
16. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
[TBL] [Abstract][Full Text] [Related]
17. The relationship between thyroid function, serum monokine induced by interferon gamma and soluble interleukin-2 receptor in thyroid autoimmune diseases.
Jiskra J; Antosová M; Límanová Z; Telicka Z; Lacinová Z
Clin Exp Immunol; 2009 May; 156(2):211-6. PubMed ID: 19250272
[TBL] [Abstract][Full Text] [Related]
18. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
Chen JJ; Ladenson PW
J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
[TBL] [Abstract][Full Text] [Related]
19. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy.
Chow CC; Lai KN; Leung JC; Chan JC; Cockram CS
Clin Endocrinol (Oxf); 1990 Sep; 33(3):317-21. PubMed ID: 2253407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]